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Introduction
Box C/D snoRNAs are short noncoding RNAs containing conserved 
C and D box consensus motifs that form ribonucleoproteins with 
NOP56, NOP58, 15.5 kDa, and the methyltransferase fibrillarin (1). 
These ribonucleoproteins localize to nucleoli, where their canoni-
cal function is to serve as guides to target specific sites on ribosomal 
RNAs (rRNAs) or small nuclear RNAs (snRNAs) for 2′-O-methyla-
tion through a short stretch of antisense complementarity (10–21 
nucleotides). In vertebrates, this function has been demonstrated 
experimentally for some box C/D snoRNAs and is predicted for 
others. The observation that animals homozygous for knockout of 
fibrillarin are inviable indicates that functions of box C/D snoRNAs 
as a class are essential for normal development (2).
Genetic studies have suggested an expanding functional rep-
ertoire for snoRNAs beyond their well-established roles in mod-
ification and processing of rRNAs and snRNAs (3). Dysregulated 
snoRNA expression has been associated with altered splicing in 
the developmental syndromes, Prader-Willi and tetralogy of Fallot 
(4, 5), and snoRNAs U50, ACA11, and ACA42 have been shown to 
modulate tumor proliferation in vivo (6–9). Nonetheless, the physi-
ological consequences of perturbation of expression of most mam-
malian snoRNAs remain unexplored, and no animal models exist 
with selective and complete loss of function for any snoRNAs.
Our laboratory’s studies have demonstrated that box C/D 
snoRNAs encoded by introns of the Rpl13a locus function as crit-
ical mediators of cell death in response to metabolic and oxida-
tive stress in cultured cells (10–12). The observations that this role 
can be dissociated from changes in the 2′-O-methylation status of 
predicted ribosomal RNA targets and that the Rpl13a snoRNAs 
accumulate in the cytosol during oxidative stress suggest that 
the Rpl13a snoRNAs may function through noncanonical mecha-
nisms. The goal of this study was to determine the physiological 
role of these noncoding RNAs.
Results
Generation of Rpl13a-snoless mice. Our previous work demon-
strated a critical role for box C/D snoRNAs U32a, U33, U34, and 
U35a, embedded within 4 introns of the Rpl13a locus (Figure 1A), 
in the cellular response to lipotoxic and oxidative stress (10). The 
observation that loss of function of the individual snoRNAs in 
cultured cells is not sufficient to confer resistance to metabolic 
stress suggests that these 4 snoRNAs function in concert in stress 
response pathways. Therefore, to probe the long-term physio-
logical consequences of loss of function of Rpl13a snoRNAs, we 
generated a model with simultaneous loss of all 4 box C/D sno-
RNAs encoded in this locus. Since deletion of the RPL13a protein 
in Drosophila is embryonic lethal (13), our goal was to selectively 
modify 4 snoRNA-hosting introns without perturbing expression 
of the exon-encoded ribosomal protein. This was accomplished 
using a single recombination event to replace the locus with an 
allele from which the snoRNAs were selectively deleted (Fig-
ure 1, A–C, and Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI88069DS1). No 
known regulatory regions overlap with these 4 snoRNAs, and 
these intronic sequences are relatively depleted of H3K27 histone 
marks that are often found near regulatory regions.
Homozygous Rpl13a snoRNA loss-of-function mice (referred 
to hereafter in text as Rpl13a-snoless and in figures as -/-) were 
live-born at normal Mendelian ratios, were fertile, and displayed 
no overt pathophysiological phenotype under standard housing, 
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suggesting that the lower peak glucose excursion resulted not 
from alterations in peripheral insulin sensitivity, but rather from 
a difference in insulin secretion.
Rpl13a-snoless islets have enhanced insulin secretion. To investi-
gate the physiological basis of increased insulin levels following a 
glucose challenge, we examined pancreatic tissue of 8-week-old 
WT and Rpl13a-snoless animals. β Cell mass as determined by 
morphometric analysis was indistinguishable between the gen-
otypes (Figure 4A). Protein and insulin content of isolated islets 
were also not different between WT and Rpl13a-snoless mice (Fig-
ure 4, B and C). Nonetheless, consistent with enhanced insulin 
secretion and glucose tolerance in vivo, Rpl13a-snoless islets had 
a 51% increase in glucose-stimulated insulin secretion (GSIS; Fig-
ure 4D). Similar insulin release from islets of the two genotypes 
in response to potassium chloride and glibenclamide indicat-
ed that the secretory machinery downstream of the KATP chan-
nel is intact in Rpl13a-snoless islets (Figure 4E). Consistent with 
increased insulin secretion at stimulatory glucose concentrations, 
Rpl13a-snoless islets demonstrated increased calcium oscillations, 
and these differences were greatest at 8 mM and 16 mM glucose 
(Figure 4F and Supplemental Figure 3). We confirmed that Rpl13a 
snoRNAs are expressed in WT, but not Rpl13a-snoless, islets (Fig-
ure 4G). Together, these findings suggest that enhanced glucose 
tolerance in Rpl13a-snoless mice results from greater islet insulin 
secretion following glucose challenge.
Increased mitochondrial leak and lower ROS in Rpl13a-snoless 
islets. Glucose stimulates insulin secretion through its metabolism 
to produce “metabolic coupling factors” that regulate the cellular 
machinery for insulin secretion (14). To assess islet glucose metab-
olism and mitochondrial function, we quantified oxygen consump-
tion rates (OCR) in isolated WT and Rpl13a-snoless islets at base-
line and following serial addition of modulators that target specific 
components of the electron transport chain. At 3 mM glucose, basal 
and maximal respiration, ATP production, and spare respiratory 
capacity were comparable between the genotypes, with a large 
feeding, and breeding conditions. Body weight and body composi-
tion were indistinguishable between Rpl13a-snoless and WT mice 
(Supplemental Figure 2, A and B). The Rpl13a-snoless mice were 
deficient in expression of the 4 intronic snoRNAs from this locus, 
but Rpl13a mRNA and protein levels were indistinguishable from 
those of WT controls (Figure 2, A and B), and expression of other 
snoRNAs was unchanged (Supplemental Figure 2C). Fibroblasts 
from Rpl13a-snoless embryos (MEFs) had significantly lower lev-
els of cellular superoxide and hydrogen peroxide under normal 
growth conditions (Figure 2, C and D). Furthermore, following 
brief exposure to exogenous hydrogen peroxide, Rpl13a-snoless 
MEFs had diminished ability to amplify ROS. Lower basal ROS 
tone and resistance to ROS stimulation are consistent with the 
phenotype of the previously reported mutant Chinese hamster 
ovary cell line, in which decreased expression of the Rpl13a sno -
RNAs caused diminished oxidative stress responses (10).
Altered glucose homeostasis in Rpl13a-snoless mice. ROS par-
ticipate in physiologic signaling cascades that regulate insulin 
secretion. Therefore, we assessed systemic glucose metabo-
lism in Rpl13a-snoless mice. Fasting plasma glucose and insulin 
levels were indistinguishable between WT and Rpl13a-snoless 
mice; however, glucose tolerance test (GTT) revealed enhanced 
glucose tolerance with lower peak glucose excursion and 
decreased AUC following an intraperitoneal glucose bolus (Fig-
ure 3A). To understand the cause of these changes in glucose 
metabolism, we used a sensitive Singulex single molecule track-
ing method to quantify fasting serum insulin and insulin levels 
at the 30-minute time point of the GTT, the point at which the 
greatest difference in serum glucose was observed between the 
genotypes. Serum insulin was significantly increased in Rpl13a- 
snoless mice at the 30-minute time point (Figure 3B), implicat-
ing enhanced release of insulin into the circulation in response 
to a glucose challenge as the cause of improved glucose toler-
ance. By contrast, glucose levels during insulin tolerance test 
(ITT) were similar between the genotypes (Figure 3C), further 
Figure 1. Generation of mice lacking Rpl13a 
snoRNAs. (A) WT locus and targeting con-
struct (–/–) with exons in black and intronic 
snoRNAs in gray rectangles. (B) Represen-
tative Southern blot from F1 (+/–) and WT 
offspring (n = 5 experiments) using probe 
indicated in A. (C) Primers (straight arrows) 
and predicted size (nucleotides) of genotyping 
PCR products, above. Representative agarose 
gel of PCR products from tail DNA is shown 
below (n > 10 experiments).
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ROS production. Given that ROS can function to inhibit GSIS (20, 
21), our findings suggest a model in which enhanced mitochondri-
al proton leak and the resulting lower ROS in Rpl13a-snoless islets 
leads to greater insulin secretion.
To gain further mechanistic insight into these observations, 
we carried out RNAseq analysis of Rpl13a-snoless and WT islets. 
We observed 2-fold or greater differences in the expression of 
only 6 genes, none of which encodes a mitochondrial protein or is 
known to have direct effects on the response to ROS (Supplemen-
tal Tables 1 and 2). None is predicted bioinformatically to have 
strong binding sites for U32a, U33, U24, or U35a (22). Our find-
ings suggest these 6 genes are unlikely to be direct targets of the 
Rpl13a snoRNAs, and effects of Rpl13a snoRNAs on gene expres-
sion may be post-transcriptional.
Rpl13a-snoless mice are resistant to diabetogenic stimuli. ROS 
have also been implicated in the pathogenesis of diabetes in animal 
models and in humans (23–27). The enhanced ROS tolerance of 
Rpl13a-snoless islets suggested that Rpl13a-snoless mice would have 
improved responses to diabetogenic stimuli. We therefore exam-
ined the susceptibility of Rpl13a-snoless mice to treatment with low 
dose streptozotocin, an antibiotic known to cause β-cell oxidative 
stress and cell death (28). After administration of streptozotocin 
or sodium citrate as control, mice were followed for an additional 
8 weeks. Hyperglycemia was less severe in streptozotocin-treated 
Rpl13a-snoless mice compared with WT mice (Figure 7A). GTT 
performed 8 weeks after streptozotocin treatment revealed lower 
blood glucose in Rpl13a-snoless mice at each time point (Figure 7B). 
In sodium citrate–treated mice, fasting blood glucose was indis-
tinguishable between the genotypes, with persistence of improved 
glucose tolerance in Rpl13a-snoless mice at 16 weeks of age (Sup-
plemental Figure 5). To gain insight into the mechanism of this pro-
tection, we harvested pancreas tissue from an independent cohort 
of animals 5 days after streptozotocin treatment. While markers of 
inflammation and β cell replication were indistinguishable between 
the genotypes (Supplemental Figure 5), streptozotocin-induced 
accumulation of the oxidatively modified lipids 4-hydroxynonenal 
and 3β,5α,6β-cholestanetriol (triol) was prevented in Rpl13a-snoless 
mice (Figure 7, C and D). Furthermore, TUNEL staining of insulin- 
positive β cells was decreased by 50% in Rpl13a-snoless animals 
proton leak relative to ATP production in both genotypes (Figure 
5A), similar to results previously described in WT islets (15). At 20 
mM glucose, basal and maximal respiration were substantially 
increased in Rpl13a-snoless islets relative to WT, which was due to 
a large increase in proton leak, but oxygen consumption for ATP 
production was not significantly different (Figure 5B). Dynamic 
OCR measurements — for which WT and Rpl13a-snoless islets 
were initially incubated in 3 mM glucose, followed by addition of 
glucose to 20 mM in the same wells — demonstrated similar OCR 
under basal conditions, with divergence in response only under 
stimulatory conditions (Figure 5C). These results indicate that 
Rpl13a-snoless islets have altered mitochondrial efficiency specifi-
cally during metabolic stress conditions. Nonetheless, morphology 
of β cell mitochondria and quantity of mitochondrial DNA per cell 
were indistinguishable between WT and Rpl13a-snoless mice (Sup-
plemental Figure 4, A and B).
Mitochondria are a major source of ROS in all cell types during 
substrate oxidation and oxidative phosphorylation, with production 
of superoxide or hydrogen peroxide at 11 distinct mitochondrial 
sites (16). Given that uncoupled respiration decreases mitochon-
drial hydrogen peroxide production during metabolic challenge (17, 
18), we hypothesized that increased proton leak in Rpl13a-snoless 
islets could lead to lower islet ROS. Similar to our observations in 
MEFs, isolated, intact islets from Rpl13a-snoless mice demonstrat-
ed a 60% decrease in basal superoxide content compared with WT 
islets, as assessed by staining with dihydroethidium (DHE) (Figure 
6A). Dissociated islets demonstrated significantly lower intracellu-
lar hydrogen peroxide (DCF) and superoxide (DHE) not only under 
basal conditions, but also following exposure to exogenous hydro-
gen peroxide (Figure 6B) or menadione, a rapid inducer of superox-
ide (Figure 6C). Consistent with the known ability of high glucose 
to induce islet ROS (19), dispersed WT islets had higher hydrogen 
peroxide content under stimulatory (20 mM) compared with basal 
(3 mM) glucose conditions (Figure 6D). Dispersed Rpl13a-snoless 
islets demonstrated significantly lower ROS under both condi-
tions. General antioxidant capacity measured in lysates of WT and 
Rpl13a-snoless islets was indistinguishable as determined using the 
Trolox equivalent antioxidant capacity assay (Supplemental Figure 
4C), suggesting that differences in ROS related to differences in 
Figure 2. Rpl13a-snoless mice demonstrate lower ROS tone. (A) RT-qPCR-quantified expression of Rpl13a snoRNAs and mRNA (relative to Rplp0) in WT and 
Rpl13a-snoless (–/–) fibroblasts. Mean + SEM for n = 3 independent experiments. (B) Representative Western blot of RPL13a protein in embryos (n = 4 mice/
genotype). (C) MitoSOX staining of embryonic fibroblasts. Mean fluorescence of 104 cells/sample (+SEM) for n = 4 independent experiments. (D) DCF staining of 
embryonic fibroblasts under basal growth conditions and following exposure to 100 μM H2O2 for 10 minutes. n = 3 independent experiments. *P < 0.005 for –/– vs. 
WT determined by unpaired t test. rel, relative.
Downloaded from http://www.jci.org on January  4, 2017.   https://doi.org/10.1172/JCI88069
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 6 1 9jci.org   Volume 126   Number 12   December 2016
islet responses to metabolic stress that impacts whole body glu-
cose homeostasis. Furthermore, the snoRNAs also modulate the 
response to stimuli that damage islets through oxidative stress, 
thereby impacting diabetes susceptibility. Together, these results 
establish that box C/D snoRNAs from the Rpl13a locus have non-
canonical functions in pancreatic β cells beyond a housekeeping 
role in the biosynthesis of ribosomal RNAs. Our findings provide 
new insights into islet biology, systemic metabolic homeostasis, 
and the pathophysiology of diabetes.
Loss of the Rpl13a-snoRNAs in this model led to enhanced 
GSIS in isolated pancreatic islets. Loss of the snoRNAs was also 
associated with increased mitochondrial proton leak, lower ROS 
tone, and diminished amplification of cellular ROS in response to 
high glucose, as well as chemicals that more directly induce ROS. 
Uncoupled respiration has been shown to decrease mitochondrial 
hydrogen peroxide production during metabolic challenge (17, 18), 
providing a precedent for our observations of increased leak and 
decreased ROS in the islets. Furthermore, high levels of ROS and 
oxidative stress are known to inhibit β cell release of insulin (19–21, 
33). Our findings suggest that under stimulatory glucose conditions, 
Rpl13a-snoless islets escape this inhibition, because they main-
tain lower oxidative tone. Together, our results suggest that in the 
Rpl13a-snoless model, mitochondrial proton leak leads to lower islet 
ROS and greater insulin secretion in the face of metabolic challenge, 
with resulting enhanced efficiency of systemic glucose metabolism.
The relationship between ROS and insulin secretion from pan-
creatic β cells is complex. These specialized cells are characterized 
by low-level expression of many antioxidant enzymes yet support 
high-level synthesis of a secreted protein that must undergo prop-
er folding and disulfide bond formation in the endoplasmic retic-
ulum, a process that is exquisitely sensitive to changes in cellular 
redox state (34–36) Furthermore, ROS function in several differ-
ent ways to regulate insulin secretion. Findings that stimulatory 
glucose levels induce mitochondrial ROS, and antioxidants that 
blunt this ROS inhibit GSIS, support a role for ROS as a stimulus 
required for GSIS (20, 37). On the other hand, high levels of ROS 
that induce oxidative stress impair GSIS, and loss of function of 
ROS-producing enzymes or scavenging of ROS potentiates GSIS 
(20, 21, 33). Specifically, high levels of ROS have been proposed to 
inhibit insulin granule exocytosis and to interfere with stimulus- 
secretion coupling in β cells (38, 39). Our observations of lowered 
provoked ROS and improved GSIS in Rpl13a-snoless islets, without 
a change in antioxidant potential, suggest that the major impact of 
loss of these noncoding RNAs is on production of ROS species that 
serve to inhibit insulin secretion.
Rpl13a-snoless mice have germline disruption of Rpl13a sno-
RNAs. Thus, although ITT responses were comparable between 
the genotypes, effects on systemic glucose homeostasis from tis-
sues other than islets cannot be formally excluded. Given our goal 
of precisely removing 4 distinct intronic sequences (ranging from 
66 to 89 nucleotides in length) within a genomic space of 2.8 kb, 
without disturbing expression of the host protein-coding sequenc-
es, we chose to knock in a “snoless” allele. Neither Cre-lox tech-
nology nor CRISPR approaches would have been feasible for gen-
eration of the 4 simultaneous conditional mutations, as this would 
have required generation and interbreeding of 4 distinct knockout 
lines to achieve tissue specificity. In our knockin model, howev-
compared with WT controls (Figure 7E). This indicates that Rpl13a 
snoRNAs function in propagation of oxidative stress in the pancreas 
and in β cell apoptosis in response to streptozotocin.
We further evaluated the effect of loss of Rpl13a snoRNAs in 
other murine models of diabetes. In the Akita model of diabetogen-
esis, the Ins2C96Y allele causes endoplasmic reticulum and oxidative 
stress, leading to β cell apoptosis and diabetes (29, 30). Loss of func-
tion of the Rpl13a snoRNAs decreased the degree of hyperglycemia 
in both male and female mice carrying the Ins2C96Y allele (Figure 
7F). In the non-obese diabetic (NOD) model, oxidative damage in 
pancreatic β cells, β cell destruction, and the development of dia-
betes are mitigated by treatment with inhibitors of ROS-producing 
enzymes, treatment with chemical ROS scavengers, or β cell– 
specific overexpression of antioxidants, independent of immune 
cell infiltration into islets (24, 31, 32). Cross of the Rpl13a-snoless 
alleles into the NOD strain revealed that loss of the snoRNAs was 
also protective against the development of hyperglycemia in the 
NOD background (Figure 7G). Taken together, our findings pro-
vide evidence that the Rpl13a snoRNAs contribute to hyperglyce-
mia in 3 independent murine models of diabetogenesis.
Discussion
Here, we identified noncanonical metabolic roles for box C/D 
snoRNAs in the physiological function and pathophysiological 
responses of β cells. Although broad loss of box C/D snoRNA–
directed 2′-O-methyl modifications of ribosomal RNAs that results 
from fibrillarin knockout is embryonic lethal (2), we demonstrate 
that selective loss of 4 snoRNAs in the Rpl13a-snoless model is 
compatible with normal murine development. Unexpectedly, 
this model revealed a role for Rpl13a-snoRNAs in regulation of 
Figure 3. Rpl13a-snoless mice have improved glucose tolerance and insulin 
secretion. (A) Mean (+SEM) blood glucose and AUC during GTT in 8-week-old 
female WT and –/– mice. n = minimum of 9 mice/genotype. (B) Mean serum 
insulin (+SEM) at 0 and 30 minutes of GTT. n = minimum of 8 mice/genotype. 
(C) Mean blood glucose (+SEM) during ITT. n = minimum of 7 mice/genotype. 
**P < 0.0005; *P < 0.05 for –/– vs. WT determined by unpaired t test.
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er, the observations that the snoRNAs are normally expressed in 
islets and that their disruption alters GSIS in isolated islets indi-
cate an islet-autonomous role for these noncoding RNAs in GSIS. 
These effects at the level of the islet are consistent with the phys-
iological observation of enhanced insulin secretion after glucose 
challenge in Rpl13a-snoless mice.
Destruction of pancreatic islets during the development of 
type 1 diabetes has been modeled in mice by chemical, genetic, 
and immunological perturbations. Although each class of mod-
els invokes different pathways leading to β cell destruction and 
eventual loss of insulin secretion and hyperglycemia, a common 
feature of these pathways is oxidative stress–mediated tissue 
damage (24–26, 29, 40). Moreover, improved outcomes following 
genetic interventions to decrease β cell ROS provide evidence that 
oxidative damage from excessive ROS contributes to destruction 
of pancreatic islets. Observations in humans of elevated plasma 
and red blood cell markers of ROS during the first weeks follow-
ing the onset of symptoms of type 1 diabetes also implicate oxi-
dative stress in the pathogenesis of diabetes (27). Our findings in 
Rpl13a-snoless mice of lower oxidative stress, less β cell death, and 
improved glucose tolerance following chemical provocation of 
diabetes and decreased hyperglycemia in genetic models of diabe-
togenesis raise the possibility that these noncoding RNAs function 
in the progressive β cell damage that leads to diabetes.
Based on the well-characterized biology of canonical sno-
RNAs, the Rpl13a snoRNAs likely form ribonucleoprotein par-
ticles that target cellular RNAs for modifications. Although our 
study links the snoRNAs to altered mitochondrial function and 
ROS production, the precise molecular targets of these snoRNAs 
responsible for the observed physiological phenotypes remain 
to be determined. Beyond the predicted 28S and 18S ribosomal 
RNA targets for these snoRNAs (41), the Rpl13a snoRNAs may 
also function non-canonically to target mRNAs, given recent 
studies demonstrating that some snoRNAs target mRNAs (42, 
43) and our previous observation that the Rpl13a snoRNAs accu-
mulate in the cytoplasm under metabolic stress conditions (12). 
Our RNAseq analysis suggests that rather than affecting the 
abundance of potential mRNA targets, the Rpl13a snoRNAs may 
impact their translation potential. Ongoing efforts are focused 
on high-throughput biochemical analyses of snoRNAs engaged 
with their relevant targets in WT tissues, studies for which the 
Rpl13a-snoless model will serve as a rigorous control. How-
ever, these approaches will be addressed in future studies, as 
they require substantially greater material than can be obtained 
from isolated islets (44). Furthermore, the Rpl13a snoRNAs may 
also contribute to metabolic stress–induced alterations in β cell 
growth and survival by binding to and activating protein kinase 
RNA-activated (PKR) to affect downstream protein translation 
and signaling pathways (45–48).
This study provides insights into the disease relevance and 
underlying cellular functions of snoRNAs in vivo. Our findings 
challenge the paradigm that box C/D snoRNAs serve solely to 
catalyze nucleotide modifications and processing of structural 
RNAs. The striking effects of loss of function of the Rpl13a sno-
RNAs raise the possibility that genetic variation affecting the pro-
duction or function of these and other snoRNAs may contribute 
to metabolic disease phenotypes in mammals. Furthermore, giv-
Figure 4. Rpl13a-snoless islets demonstrate enhanced glucose-stimulated 
insulin secretion. (A) Representative insulin-stained pancreas sections with 
morphometric quantification of β cell mass for WT and Rpl13a-snoless (–/–) 
mice (n = 4 mice/genotype). Mean + SEM; n = 4 mice/genotype; scale bars:  
25 μm. (B) Mean islet protein content (+SEM) quantified in 8 mice/genotype  
(10 islets/mouse) obtained from 3 independent experiments. (C) Mean islet 
insulin content (+SEM) quantified in 12 mice/genotype (10 islets/mouse) 
obtained from 3 independent experiments. (D) Mean islet insulin secretion 
(+SEM) in response to low and high glucose quantified in a minimum of 9 mice/
genotype over 3 independent experiments. (E) Mean islet insulin secretion 
(+SEM) in response to 30 mM KCl and 1 μM glibenclamide quantified in 3–4 
mice/genotype over 3 independent experiments. (F) Changes in Fluo-4– 
quantified calcium activity of islets relative to basal, expressed as Δf/f0 for 
differing glucose concentrations. Data from 20 independent cells from 4 mice/
genotype. (G) RT-qPCR-quantified expression of Rpl13a snoRNAs and mRNA in 
islets (relative to Rplp0). n = 3 independent islet preparations/genotype.  
**P < 0.001; *P < 0.05; for –/– vs. WT determined by unpaired t test.
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en that snoRNAs can be targeted for antisense knockdown, our 
findings suggest that molecular therapies could be designed to 
target these noncoding RNAs.
Methods
Mice. To generate mice lacking all 4 Rpl13a snoRNAs, we created a tar-
geting vector containing the Rpl13a sequence between exons 1 and 8 
with a loxP-flanked neomycin phosphotransferase (NEO) cassette in 
intron 1, and lacking the U32a, U33, U34, and U35a snoRNAs in introns 
2, 4, 5, and 6, respectively. The construct was electroporated into 
129S5/SvEv ES cells. ES cells with the correct homologous recombina-
tion event were selected by neomycin resistance, PCR, and Southern 
blot analysis. ES clones with normal karyotype were microinjected into 
B6/FBN blastocysts that were implanted into pseudopregnant females. 
F1 progeny from the resulting chimeras were tested for the presence of 
the NEO cassette in the Rpl13a locus by Southern blot analysis. The 
NEO cassette was removed by breeding these mice with mice express-
ing CRE under the adenovirus EIIa promoter. Heterozygote progeny 
were backcrossed into the FVB/N strain more than 10 generations. See 
Supplemental Table 3 for genotyping primers. Mice generated from 
heterozygote-heterozygote breeding pairs were used for experiments. 
The Rpl13a-snoless mice were crossed with Akita mice bearing the 
Ins2C96Y allele, which had previously been backcrossed onto the FVB 
background for more than 9 generations (FVB.B6-Ins2Akita/MlnJ; 
The Jackson Laboratory). NOD (NOD/ShiLtJ) mice from the Jackson 
Laboratory were bred in the Immunology of Type 1 Diabetes Core of 
the Washington University Diabetes Research Center. Speed Con-
genics (49) was used to move the Rpl13a-snoless allele onto the NOD 
background strain, using a marker-assisted breeding strategy. At each 
generation, multiple offspring were analyzed for genomic single nucle-
otide polymorphisms to select subsequent breeders with the highest 
percentage of NOD. After 6 generations, animals were >98.2% NOD. 
NOD/Rpl13a+/– breeders were used to generate female progeny for 
studies. Diabetic mice were identified based on two consecutive ran-
dom blood glucose measures of ≥250 mg/dl.
RT-qPCR. Total RNA was isolated using TRIzol reagent. For 
mRNA analyses, cDNA synthesis used the SuperScript First-Strand 
Synthesis System with oligo(dT) priming (Invitrogen). For snoRNA 
analyses, stem-loop primers were used for reverse transcription, as 
previously described (10, 50). Quantitative RT-PCR (RT-qPCR) was 
performed using SYBR Green PCR Master Mix (Applied Biosystems) 
and an ABI Prism 7500 Fast Real-Time PCR System. Relative quan-
tification of gene expression was performed using the comparative 
threshold method. See Supplemental Table 3 for RT-qPCR primers.
Immunoblot analyses. Tissues were homogenized in RIPA buf-
fer (150 mM NaCl, 50 mM HEPES pH 7.4, 1% Nonidet P-40, 0.1% 
SDS, 0.5% sodium deoxycholate, 1× Protease Complete [Roche], 
1 mM phenylmethylsulfonyl fluoride). Proteins were separated by 
SDS-PAGE, transferred to nitrocellulose using the semi-dry method, 
blocked with dry milk, and immunoblotted with polyclonal rabbit 
α–hamster RPL13a antibody (1:2,000) (10) and monoclonal α-actin 
(Sigma-Aldrich). Detection used HRP-conjugated secondary anti-
Figure 5. Increased mitochondrial leak 
in Rpl13a-snoless islets. (A) OCR of WT 
and –/– islets at 3 mM glucose with 
injection of oligomycin (OM), FCCP, and 
rotenone and antimycin A (Rot/AntA). 
Data points in line graphs (left) represent 
mean values (±SEM) from 3 independent 
experiments in which islets pooled by 
genotype were used to generate a total 
of 9 (WT) or 8 (–/–) technical replicates 
from n = 11 WT and n = 12 –/– mice. 
Bar graphs (right) report calculated 
mean (+SEM) oxygen consumption for 
basal and maximal (Max) respiration, 
proton leak, ATP production and spare 
respiratory capacity. (B) OCR of WT and 
–/– islets at 20 mM glucose, as in A. Data 
points from 3 independent experiments 
in which islets pooled by genotype were 
used to generate a total of 9 (WT) or 
11 (–/–) technical replicates from n = 13 
WT and n = 14 –/– animals. Graphs as in 
A. (C) OCR of WT and –/– islets initially 
maintained at 3 mM glucose; this was 
changed at the time indicated to 20 mM 
glucose. Data points represent mean 
values (±SEM) from 3 independent 
experiments in which islets pooled by 
genotype generated 12 (WT) or 8 (–/–) 
technical replicates from n = 15 WT and 
n = 10 –/– animals. *P < 0.05 for –/– vs. 
WT; **P < 0.01 for –/– vs. WT determined 
by unpaired t test.
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bodies (Jackson ImmunoResearch Laboratories) and Western Light-
ning Plus-ECL (PerkinElmer Life Sciences) reagent. Images were 
digitally captured using a Bio-Rad ChemiDoc MP and analyzed with 
Bio-Rad Image Lab software.
Islet isolation. Pancreases were inflated with ice-cold collagenase 
(Sigma-Aldrich) buffer (0.45 mg/ml collagenase in HBSS without 
Ca2+) and digested at 37°C. Islets were collected after sequential wash-
es and incubated overnight in RPMI media (with 10% FBS and 2 mM 
l-glutamine) until use (51). Islets of equal size were hand picked to 
generate 3–5 technical replicates (measures, wells) for all experiments. 
Very large and very small islets were excluded. Results are reported for 
a minimum of 3 independent experiments.
Insulin secretion assay. Hand-picked islets were distributed into 
0.4-μm Transwells of a 24-well plate containing Krebs-Ringer buf-
fer (KRB) without glucose. After washing twice in 2.8 mM glucose, 
islets were sequentially incubated in 5.6 mM and 16.7 mM glucose 
for 1 hour each (52). For KCl and glibenclamide experiments, islets 
were incubated first in 5.6 mM glucose and then 30 mM KCl or 1 μM 
glibenclamide (Sigma-Aldrich). A Rat/Mouse Insulin ELISA kit (Mil-
lipore) was used to measure the insulin levels in media.
Calcium imaging of islets. Hand-picked islets were loaded with 4 
μM Fluo-4 (Invitrogen) in KRB with 20 mM HEPES and 0.1% BSA, 
pH 7.4, for 40 minutes and then imaged on a Zeiss LSM 880 confo-
cal microscope (Plan-Apochromat 20× M27, NA0.8 objective) in 2, 
5, 8, and 16 mM glucose, with analyses as previously described (53). 
Following a 6-minute incubation at each concentration, a 5-minute 
time series was acquired, and 20 mM KCl was injected at the end of 
acquisition to prime maximum calcium release. Data were analyzed 
using ImageJ (NIH) and  averaged over 20 cells in 6 different islets 
from each of 4 different mice per genotype. Data are expressed as 
fluorescence intensity under each condition relative to basal (non-
treated) conditions.
ROS detection from whole islets or dispersed islet cells. For whole islets, 
equivalent numbers of hand-picked islets of each genotype were incu-
bated in media containing 10 μM DHE (Molecular Probes) for 1 hour, 
washed with PBS, and mounted. Epifluorescence images were obtained 
using a Zeiss Axioskop, and DHE fluorescence was quantified in 6 ran-
dom fields per sample using ImageJ. For dispersed islets, equivalent 
numbers of cells of each genotype (pooled from multiple animals) 
were plated in RPMI media in 96-well plates overnight, incubated with 
10 μM DHE or 10 μM H2DCFDA (DCF; Molecular Probes) for 1 hour, 
and then treated with 100 μM H2O2 (Sigma-Aldrich) for 2 hours. Fluo-
rescence was quantified in each well using a TECAN plate reader. To 
detect ROS production in low- (3 mM) or high-glucose (20 mM) con-
ditions, dispersed islets were plated on poly-d-lysine–coated (Sigma- 
Aldrich) glass-bottom culture dishes (MatTek Corp.). After overnight 
culture, islets were incubated in KRB containing 3 mM or 20 mM glu-
cose with 10 μM DCF for 1 hour at 37°C. Immediately after washing, 
fluorescence images were obtained using a Leica DMIRB microscope. 
DCF fluorescence of individual islet cells from 8–10 random fields per 
condition was quantified using Leica Application Suite AF (19).
Trolox equivalent antioxidant capacity. Antioxidant capacity was 
quantified in lysates from hand-picked islets (n = 4 mice/genotype) 
as described previously, and values are reported per microgram 
islet protein (54).
RNAseq analysis of islets. High-quality total RNA (RNA integri-
ty number [RIN] ≥8.5) was prepared from hand-picked islets (n = 4 
mice/genotype) using TRIzol reagent, treated with TURBO DNAse 
(Thermo Fisher), and used to prepare SeqPlex RNAseq libraries 
(Sigma-Aldrich). Sequencing was performed by the Washington 
University Genome Technology Access Center using two lanes of 
Illumina HiSeq 2500. Reads were demultiplexed and trimmed, and 
STAR alignment and quantification analysis were carried out using 
the Partek Flow platform. Uniquely aligned reads were quantified to 
identify genes with at least a 2-fold change between genotypes, with 
P < 0.05 and an FDR step-up of 0.05. Genes identified were further 
analyzed for potential U32a, U33, U34, and U35a snoRNA target sites 
using the PLEXY program and a cut-off of minimum free energy for 
predicted duplexes of less than –20.4 kcal/mol (22). Sequence data are 
available in the NCBI’s Gene Expression Omnibus (GEO GSE87354).
Streptozotocin treatment. Eight-week-old female mice were inject-
ed with streptozotocin intraperitoneally (Sigma-Aldrich; 50 mg/kg in 
0.1 M Na citrate, pH 4.5) for 5 consecutive days as previously described 
(55). Control animals received buffer only. Serial fasting blood glucose 
and body weight were quantified every 2 weeks; GTT was performed 
at 8 weeks after the streptozotocin injection, and pancreases were har-
vested for histological analysis.
Intraperitoneal GTT and ITT. In vivo dynamic testing was car-
ried out following a 4-hour fast using standard procedures of the 
NIH-sponsored National Mouse Metabolic Phenotyping Centers 
Figure 6. Rpl13a-snoless islets are ROS resistant. (A) Representative images of WT and –/– islets (n = 3 mice/genotype) stained for superoxide with DHE. Scale 
bar: 50 μm. Graph shows mean fluorescence (+SEM) of WT and –/– islets for n = 6 random fields/genotype in each of 2 independent experiments. (B and C) DCF 
and DHE staining of dispersed islets at baseline and following treatment for 2 hours with 100 μM H2O2 (B) or 25 μM menadione (mdn; C). Mean (+SEM) of data 
from a minimum of 3 independent experiments. (D) DCF staining (mean + SEM) of dispersed islets incubated for 2 hours with 3 mM or 20 mM glucose. Data from 
3 independent experiments. *P < 0.05 for –/– vs. WT; #P < 0.05 for treated vs. untreated (within a genotype) determined by unpaired t test.
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with α–Ki-67 antibodies (anti-rabbit monoclonal IgG, 1:200, Cell 
Signaling Technology 9129), quantified from >75 islets per condition 
(n = 4 mice [>3,500 nuclei]/genotype/condition). Secondary antibod-
ies were Alexa Flour 488–goat anti-guinea pig and Alexa Fluor 594–
goat anti-rabbit (Molecular Probes A-11073 and A-11037). Stained sec-
tions were examined using an Olympus FSX100 microscope.
Morphometry. Morphometric analysis of pancreases from 8-week-old 
mice was performed as previously reported (56). For measurement of β 
cell mass, every 40th pancreatic section was immunostained with guin-
ea pig anti-insulin antibody (1:100, Invitrogen) and counterstained with 
hematoxylin. The β cell mass for each mouse was quantified using Image 
Pro Plus software (Media Cybernetics) by obtaining the fraction of the 
cross-sectional area of pancreatic tissue (exocrine and endocrine) positive 
for insulin staining and then multiplying by the pancreatic weight.
Isolation of MEFs and ROS detection. MEFs were harvested 
from embryos at E13.5 and cultured in DMEM with 10% FBS, 2 mM 
(http://www.mmpc.org/shared/protocols.aspx). Mice were inject-
ed intraperitoneally with 1 g/kg glucose (GTT) or 1 U/kg insulin 
(ITT). Blood glucose was measured at 0, 15, 30, 60, and 120 min-
utes after the injection using a glucometer (Contour). Serum was 
analyzed for insulin at 0 and 30 minutes of GTT at the Washing-
ton University Diabetes Research Center Immunoassay Core by a 
sensitive Singulex single molecule tracking method that has a lower 
limit of quantification of 19 pg/ml.
Histological and immunofluorescence analyses. For histological 
analyses, 5-μm sections of formalin-fixed, paraffin-embedded pan-
creas tissues were stained with H&E. For TUNEL, sections were 
labeled with TUNEL reagent (Cell Death Detection Kit TMR, Roche), 
followed by overnight incubation with α-insulin antibodies (poly-
clonal guinea pig antibody, 1:200, Dako IR002). TUNEL-positive 
signals were quantified from >75 islets per condition (n = 4 mice 
[>5,000 nuclei]/genotype/condition). Proliferation was analyzed 
Figure 7. Rpl13a-snoless mice are resistant to diabetogenic stimuli. (A–E) streptozotocin- (STZ-) or vehicle-treated (control) 8-week-old WT and –/– mice. (A) 
Mean fasting blood glucose over time (+SEM) for n = 9 mice per genotype/treatment. (B) Mean blood glucose (+SEM) during GTT at 16 weeks for n = 9 mice per gen-
otype/treatment. (C) Representative pancreas sections stained for 4-hydroxynonenal 5 days after STZ. Scale bar: 25 μm (n = 4 mice per genotype/treatment). (D) 
Pancreas tissue triol 5 days after STZ for n = 7 mice per genotype/treatment. (E) Representative pancreas sections stained for TUNEL 5 days after STZ. Scale bar: 
25 μm. Quantification for n = 4 mice per genotype/treatment. Magnification ×2. (F) Ins2C96Y Akita allele bred into Rpl13a-snoless model. Mean (+SEM) random blood 
glucose at indicated time points for a minimum of n = 7 per group. (G) Rpl13a-snoless alleles were bred into the NOD model. Diabetes-free survival over 24 weeks 
for NOD (n = 26) vs. NOD Rpl13a-snoless (n = 16) female mice. *P < 0.05 for (–/–, STZ) vs. (WT, STZ); **P < 0.05 for (WT, STZ) vs. (WT); #P < 0.001 for (WT, C96Y) vs. 
(WT); †P < 0.0005 for (–/–, C96Y) vs. (WT, C96Y); determined by unpaired t test. §P < 0.04 by log-rank testing. 
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2-tailed Student’s t test or log-rank test. P < 0.05 was considered signifi-
cant. Serial glucose and GTT for streptozotocin-treated WT and knock-
out mice (Figure 7) were compared using multiple unpaired t tests and 
corrected for multiple comparisons using the Šidák-Bonferroni method, 
with α of 0.05.
Study approval. Animal studies were approved by the Institutional 
Animal Care and Use Committee of Washington University in St. Louis.
Author contributions
JL and JES designed the study in consultation with FU, MSR, DWP, 
and DSO. Experiments were performed by JL, ANH, CLH, JM, 
KDP, ZL, DES, HF, RS, JZ, and SCCH. The manuscript was written 
by JL and JES. All authors contributed to editing the manuscript 
and support the conclusions.
Acknowledgments
This work was supported by NIH 2 R01 DK064989, Fondation 
Leducq (12CVD04), the Juvenile Diabetes Research Foundation 
(1-INO-2014-179-A-V), and the American Diabetes Association 
(7-09-CVD-07) (to JES); by NIH R01 DK098584 (to MSR); and by 
the Washington University Diabetes Research Center (Transgenic 
and ES Cell, Morphology and Metabolic Analysis, Immunoassay, 
Diabetes Models Phenotyping, Mass Spectrometry, and Immunolo-
gy of Type 1 Diabetes Cores; P30 DK020579). Calcium imaging was 
performed at the Washington University Center for Cellular Imag-
ing. We thank the Genome Technology Access Center in the Depart-
ment of Genetics at Washington University School of Medicine for 
help with RNAseq analyses. The Center is partially supported by 
an NCI Cancer Center Support grant to the Siteman Cancer Center 
(NIH P30 CA91842) and by the Washington University Institute of 
Clinical and Translational Sciences/Clinical & Translational Science 
Award (ICTS/CTSA) (NIH UL1 TR000448).
Address correspondence to: Jean E. Schaffer, 660 South Euclid 
Avenue, Campus Box 8086, St Louis, Missouri 63110, USA. Phone: 
314.362.8717; E-mail: jschaff@wustl.edu.
l-glutamine, 1× MEM non-essential amino acids, and 150 μM 
monothioglycerol. ROS was quantified in low-passage (≤5) MEFs by 
staining with 10 μM DCF or 5 μM MitoSOX Red (Life Technologies) 
for 5 minutes in PBS with Ca2+/Mg2+. Fluorescence intensity was quan-
tified by flow cytometry (BD FACSCalibur), measuring mean signal 
intensity for 104 events in each sample, and normalized to WT cells.
Oxidative tissue damage. Formalin-fixed pancreatic sections were 
costained for insulin (polyclonal guinea pig antibody, 1:200, Dako) and 
hydroxynonenal (rabbit polyclonal, 1:100, Abcam) using appropriate 
Alexa Fluor–coupled secondary antibodies (Molecular Probes). Triol was 
quantified per mg pancreas tissue and is reported per mg protein (57).
Mitochondrial DNA copy number. Relative mitochondrial DNA 
content was measured from isolated islets using RT-qPCR and nuclear 
DNA content as an internal control, as described previously (58).
OCR. Oxygen consumption of islets was measured using a 
Seahorse XF24 analyzer (Seahorse Bioscience) (15). Fifty islets were 
hand picked and washed once in assay media containing 1% FBS and 
1 mM l-glutamine, and 3 mM or 20 mM glucose, and then transferred 
into the depressed well of an XF24 Islet Capture Microplate. OCR was 
measured at basal glucose levels, as well as with drugs acting on the 
respiratory chain: oligomycin (ATP synthase inhibitor; 5 μM), FCCP 
(uncoupler; 7.5 μM), rotenone (complex I inhibitor; 0.1 μM), and anti-
mycin A (complex III inhibitor; 1 μM) — all from Sigma-Aldrich. After 
the assay, islets were washed once with PBS, and protein was quanti-
fied by microBCA assay (Pierce).
Electron microscopy. Islets were fixed in a modified Karnovsky’s 
fixative of 3% glutaraldehyde, 1% paraformaldehyde in 0.1 M sodium 
cacodylate buffer; post-fixed in 2% osmium tetroxide in 0.1 M sodium 
cacodylate buffer; stained with 2% aqueous uranyl acetate for 30 min-
utes; dehydrated in graded acetone; and embedded in Poly/Bed 812 
(Polysciences Inc.). 90-nm sections were examined by a JEOL model 
1200EX electron microscope. Digital images were acquired using the 
AMT Advantage HR (Advanced Microscopy Technology) high-definition 
CCD, 1.3 megapixel TEM camera.
Statistics. Results are presented as mean ± SEM for a minimum of 
3 independent experiments. Statistical significance was assessed by 
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